on Thursday, September 13, 2012
Dr. Armstrong has made significant contributions to the understanding of the origins of leukemia. He has joined Memorial Sloan Kettering as a Member in the Department of Pediatrics and the Human Oncology and Pathogenesis Program.
Scott A. Armstrong has joined Memorial Sloan Kettering Cancer Center as a Member in the Department of Pediatrics and the Human Oncology and Pathogenesis Program. A pediatric oncologist, he uses genome-wide technologies to characterize the molecular pathways responsible for leukemia development with a focus on the relationship between normal and leukemic stem cells. In particular, he has made major contributions to the understanding of the pathogenesis of a high-risk form of acute leukemia associated with a distinctive chromosomal rearrangement that occurs in both children and adults. His landmark findings have pointed to potential new leukemia therapies.
Dr. Armstrong comes to Memorial Sloan Kettering from Children’s Hospital Boston, Dana-Farber Cancer Institute, where he was Co-Director of the Leukemia Program in the Dana-Farber/Harvard Cancer Center and Co-Director of the Harvard Stem Cell Institute Cancer Program. He obtained his MD and PhD degrees from the University of Texas Southwestern Medical School. He completed an internship and residency at Children’s Hospital Boston and a clinical fellowship at Dana-Farber Cancer Institute.
The importance of his contributions to the understanding of the origins of leukemia has been widely recognized. In 2011, he received the Paul Marks Prize for Cancer Research from Memorial Sloan Kettering. He was also an early recipient of the Damon Runyon Eli Lilly Clinical Investigator Award and received the McCulloch and Till Award from the International Society of Experimental Hematology as well as the E. Mead Johnson Award in Pediatric Research.